NUVB

Over the past six months, Nuvation Bio's stock was impacted by several events: the FDA approved a supplemental New Drug Application for IBTROZI in September 2026, updating its label to reflect a median duration of response of 49.7 months in TKI-naïve ROS1-positive NSCLC patients, which caused shares to surge. New subgroup data presented at WCLC 2026 further reinforced IBTROZI's durable efficacy. Analysts maintained positive ratings and price targets, with RBC Capital affirming an 'Outperform' rating and a $19.00 target in July 2026, and a consensus 'Moderate Buy' with an average target of $13.22 in October 2026, though Wall Street Zen downgraded to 'sell' in October 2026. For the quarter ending June 30, 2026, the company reported revenue of $31.69 million, exceeding estimates, but a quarterly loss of $0.15 per share, slightly missing estimates, with IBTROZI net revenue growing 25% quarter-over-quarter. Updated Phase 2 data for safusidenib in July 2026 showed a 52% objective response rate and 79% 36-month progression-free survival in IDH1-mutant glioma patients, leading to plans for clinical program expansion. Nuvation Bio also raised $287.5 million through a convertible notes offering in July 2026, strengthening its balance sheet. Despite positive news, the stock experienced volatility, trading within a 52-week range of $3.36 to $9.75.